| 1415570-83-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• CAS: 1415570-83-0
• 化学式: C₂₅H₃₀N₄O₃
• 分子量: 434.538
• InChiKey: DJCUYZBMZWZJII-UAPYVXQJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.64
• 重原子数：
  32.0
• 可旋转键数：
  6.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  91.34
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  2-氟吡啶-5-甲醛 在 oxone 、 水 、 sodium carbonate 、 溶剂黄146 、 lithium hydroxide 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成
  参考文献：
  名称：

  Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC)

  摘要：

  The parallel medicinal chemistry (PMC) was effectively applied to accelerate the optimization of diacylglycerol O-acyltransferase I (DGAT-1) inhibitors. Through a highly collaborative and iterative library design, synthesis and testing, a benzimidazole lead was rapidly and systematically advanced to a highly potent, selective and bioavailable DGAT1 inhibitor with the potential for further development.

  DOI：

  10.1016/j.bmcl.2019.03.039

文献信息

• [EN] IMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLE
  申请人：INTERVET INT BV

  公开号：WO2012164071A1

  公开（公告）日：2012-12-06

  Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述了式(I)的化合物。式(I)的化合物作为DGAT1抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的治疗药物。
• IMIDAZOLE DERIVATIVES
  申请人：DeVita Robert J.

  公开号：US20140088124A1

  公开（公告）日：2014-03-27

  Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述了化学式（I）的化合物。化合物I的作用是DGAT1抑制剂，可以用于预防，治疗或作为治疗高脂血症，糖尿病和肥胖症的药物。
• Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC)
  作者：Yang Yu、Zhicai Wu、Zhi-Cai Shi、Shuwen He、Zhong Lai、Timothy A. Cernak、Petr Vachal、Min Liu、Jian Liu、Qingmei Hong、Tianying Jian、Deodial Guiadeen、Arto Krikorian、Donald M. Sperbeck、Andreas Verras、Lisa M. Sonatore、Beth A. Murphy、Judyann Wiltsie、Christine C. Chung、Judith N. Gorski、Jinqi Liu、Jianying Xiao、Michael Wolff、Sharon X. Tong、Maria Madeira、Bindhu V. Karanam、Dong-Ming Shen、James M. Balkovec、Robert J. De Vita、Shirly Pinto、Ravi P. Nargund

  DOI：10.1016/j.bmcl.2019.03.039

  日期：2019.6

  The parallel medicinal chemistry (PMC) was effectively applied to accelerate the optimization of diacylglycerol O-acyltransferase I (DGAT-1) inhibitors. Through a highly collaborative and iterative library design, synthesis and testing, a benzimidazole lead was rapidly and systematically advanced to a highly potent, selective and bioavailable DGAT1 inhibitor with the potential for further development.